title: The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade.
abstract: During the last decade it has been shown that some components of intravenous immunoglobulin (IVIG) are responsible for their broadly therapeutic application. Currently, such specific subfractions are defined as specific IVIG (sIVIG) and are affinity-purified from commercial IVIGs that target specific antigens/antibodies related to a specific autoimmune disease. A remarkable example of the therapeutic potential of sIVIG is the proven enhanced anti-inflammatory potency of sialylated and recombinant sialylated IVIG obtained from total IVIG. In other experimental models, it has also been demonstrated that sIVIG work in many other contrivances, such as revealing anti-idiotypic networks blocking pathogenic antibodies ameliorating disease activity. sIVIG has also been shown to exert its action by modulating specific receptors expressed on immune cells in both inflammatory and autoimmune diseases. Indeed, sIVIG has emerged as a novel approach to treat different immune-mediated conditions in a more accurate antigen-specific manner. Herein we review experimental evidence supporting sIVIG-efficacy in treating autoimmune diseases and inflammation.
authors.affiliation: Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: Nina
authors.initials: N
authors.lastname: Svetlicky
authors.forename: Oscar-Danilo
authors.initials: OD
authors.lastname: Ortega-Hernandez
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.forename: Loic
authors.initials: L
authors.lastname: Guillevin
authors.forename: Hans-Jurgen
authors.initials: HJ
authors.lastname: Thiesen
authors.forename: Arie
authors.initials: A
authors.lastname: Altman
authors.forename: Martine Szyper
authors.initials: MS
authors.lastname: Kravitz
authors.forename: Miri
authors.initials: M
authors.lastname: Blank
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000276:immunology / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000888:Antibodies, Anti-Idiotypic; D001324:Autoantigens; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors